SCHEMBL26554496

CC(=O)NC1[C@H](OC2[C@@H](OCC3O[C@@H](O[C@@H]4C(CO)O[C@@H](O)C(NC(C)=O)[C@H]4O)C(O)[C@@H](O[C@H]4O[C@@H](CO)[C@@H](O)C(O)C4O[C@@H]4OC(CO)[C@@H](O[C@@H]5OC(CO[C@]6(C(=O)NCCOCCOCCOCCN=[N+]=[N-])C[C@@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@H](O)CO)O6)[C@H](O)[C@H](O)C5O)[C@H](O)C4NC(C)=O)[C@@H]3O)OC(CO)[C@@H](O)[C@@H]2O)OC(CO)[C@@H](O[C@H]2C[C@@H](O)[C@@H](O)C(CO[C@]3(C(=O)NCCOCCOCCOCCN=[N+]=[N-])C[C@@H](O)[C@@H](NC(C)=O)C(CO)([C@H](O)CO)O3)O2)[C@@H]1O

nearest known ligand 0.54

Predicted protein targets (top 4)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.54

▸	MAG	P20916	11/20	0.42

▸	SELE	P16581	1/20	0.38

▸	CD209	Q9NNX6	1/20	0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL26554524	0.92	SIGLEC7 (0.49)	SIGLEC7MAGSELE
SCHEMBL26554465	0.89	SIGLEC7 (0.56)	SIGLEC7MAGSELE
SCHEMBL26554564	0.86	SIGLEC7 (0.53)	SIGLEC7MAGSELECD209
SCHEMBL26554536	0.83	SIGLEC7 (0.61)	SIGLEC7MAGSELE
SCHEMBL24191529	0.83	SIGLEC7 (0.55)	SIGLEC7MAGSELECD209
SCHEMBL24191630	0.83	SIGLEC7 (0.55)	SIGLEC7MAGSELECD209
SCHEMBL13004041	0.79	SIGLEC7 (0.65)	SIGLEC7MAGSELE
SCHEMBL30532209	0.79	SIGLEC7 (0.65)	SIGLEC7MAGSELE
SCHEMBL17447134	0.77	SIGLEC7 (0.69)	SIGLEC7MAGSELECD209
SCHEMBL14570810	0.77	SIGLEC7 (0.62)	SIGLEC7MAGSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230330248-A1	ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE	DAIICHI SANKYO COMPANY, LIMITED (JP)	2023-10-19	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230330248-A1	ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE	STING1, CGAS, TLR9	SIGLEC7 141/4885MAG 1875/4885SELE 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.